Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFATINIB vs BLINCYTO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.
Bispecific CD19-directed CD3 T-cell engager; binds CD19 on B cells and CD3 on T cells, activating endogenous T cells to lyse CD19-expressing B cells.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations,Treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy,Off-label: Use in other EGFR-mutant cancers (e.g., head and neck cancer, colorectal cancer) with specific mutations
Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1% in adults and children
40 mg orally once daily, continuously.
Continuous intravenous infusion over 28 days per cycle. For patients ≥45 kg: 9 mcg/day on days 1-7 and 28 mcg/day on days 8-28 for cycle 1, then 28 mcg/day on days 1-28 for subsequent cycles. For patients <45 kg: 5 mcg/m2/day on days 1-7 and 15 mcg/m2/day on days 8-28 for cycle 1, then 15 mcg/m2/day on days 1-28 for subsequent cycles. Hospitalization recommended for first 9 days of cycle 1 and first 2 days of subsequent cycles.
Terminal half-life is approximately 37 hours; supports once-daily dosing with steady-state achieved within 8 days.
The terminal elimination half-life of blinatumomab is approximately 2.11 hours (range 1.2–2.5 hours) during continuous intravenous infusion. The short half-life necessitates continuous infusion to maintain therapeutic concentrations.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP3A4-independent pathways including flavin-containing monooxygenase (FMO). Excretion mainly via feces (85%) and urine (4%) as unchanged drug and metabolites.
Metabolized to small peptides by catabolic pathways; not metabolized by CYP enzymes.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <4% of the dose.
Blinatumomab is not metabolized by cytochrome P450 enzymes; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion studies have been conducted; however, clearance is primarily through non-specific proteolysis, and no significant renal or biliary excretion of intact drug occurs. The contribution of renal elimination to total clearance is minimal (<1%).
Approximately 95% bound to plasma proteins, primarily to albumin.
Blinatumomab is a monoclonal antibody; protein binding is negligible at clinically relevant concentrations. No specific binding to plasma proteins has been reported.
Volume of distribution is approximately 2300 L (about 33 L/kg for a 70 kg individual), indicating extensive tissue distribution.
The volume of distribution (Vd) at steady state is approximately 3.13 L (range 2.35–4.38 L), corresponding to about 0.04 L/kg (assuming 70 kg body weight), suggesting limited extravascular distribution consistent with a large monoclonal antibody.
Oral bioavailability is approximately 92% relative to an oral solution; food reduces exposure, so take on an empty stomach.
Blinatumomab is administered as a continuous intravenous infusion; bioavailability by this route is 100%. No other routes are clinically relevant.
No starting dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to safety concerns.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min) or dialysis, use with caution and monitor for increased toxicity; specific dose adjustments not established.
Child-Pugh A: 40 mg once daily. Child-Pugh B: Reduce dose to 30 mg once daily. Child-Pugh C: Not recommended due to lack of data.
No dedicated Child-Pugh based adjustments available. Use with caution in patients with moderate to severe hepatic impairment; monitor for hepatotoxicity.
Safety and efficacy not established in pediatric patients; no specific dosing recommendations.
For patients weighing ≥45 kg: same as adult dosing. For patients <45 kg: based on body surface area (BSA). Cycle 1: 5 mcg/m2/day (max 9 mcg/day) on days 1-7, then 15 mcg/m2/day (max 28 mcg/day) on days 8-28. Subsequent cycles: 15 mcg/m2/day (max 28 mcg/day) on days 1-28. Administer as continuous IV infusion over 28 days.
No specific dose adjustment recommended based on age alone; monitor renal function and tolerability, as elderly patients may have decreased renal function or comorbidities.
No specific dose adjustment recommended for elderly patients. Monitor closely for adverse reactions, particularly neurologic events and infections, as clinical studies included limited patients aged ≥65 years.
None.
Cytokine release syndrome (CRS), which may be life-threatening or fatal; neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe or fatal.
Severe diarrhea (including dehydration and acute kidney injury),Interstitial lung disease (ILD)/pneumonitis,Severe hepatotoxicity (elevated liver enzymes, hepatitis),Left ventricular dysfunction (assess LVEF at baseline and during treatment),Severe bullous, blistering, and exfoliative skin reactions (e.g., Stevens-Johnson syndrome),Gastrointestinal perforation,Ocular toxicities (keratitis, conjunctivitis),Renal toxicity (proteinuria, nephrotic syndrome),Fetal harm (embryo-fetal toxicity),Drug interactions with CYP3A4 inducers or inhibitors
Cytokine release syndrome, neurological toxicities (including ICANS), infections, neutropenia and febrile neutropenia, tumor lysis syndrome, leukopenia, increased liver enzymes, pancreatitis, preparation and administration errors, and embryo-fetal toxicity.
None reported,Relative contraindications: pre-existing severe hepatic impairment, severe renal impairment, pregnancy, and breastfeeding
Known hypersensitivity to blinatumomab or any component of the formulation.
Take on an empty stomach (at least 1 hour before or 2 hours after food). Avoid grapefruit, grapefruit juice, and Seville oranges as they may alter drug metabolism. High-fat meals reduce absorption.
No clinically significant food interactions reported. Grapefruit and grapefruit juice do not affect blinatumomab as it is a monoclonal antibody not metabolized by CYP450 enzymes. No dietary restrictions required.
Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neural tube defects based on animal studies showing embryotoxicity and teratogenicity at doses below human exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and impaired renal function due to inhibition of EGFR signaling critical for fetal development.
Based on its mechanism of action (CD19-directed bispecific T-cell engager) and animal studies, blinatumomab may cause fetal harm. Ig G molecules cross the placenta, with increasing transfer in the second and third trimesters. Limited human data exist; however, it is expected to pose a risk of fetal B-cell lymphopenia, immunomodulation, and potential teratogenicity. Use during pregnancy should be avoided unless the benefit clearly outweighs the risk.
No human data on afatinib excretion in breast milk; however, animal studies indicate drug presence in milk. M/P ratio is unknown. Due to potential for serious adverse effects in breastfed infants, breastfeeding is contraindicated during therapy and for at least 2 weeks after the last dose.
There are no data on blinatumomab presence in human milk, effects on the breastfed child, or milk production. Due to the potential for serious adverse reactions from a large Ig G protein, breastfeeding is not recommended during treatment and for at least 48 hours after the last dose.
No specific dosing guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may occur but studies have not established dose adjustments. The drug should be avoided in pregnancy unless benefit outweighs risk; if used, consider therapeutic drug monitoring if available.
No specific dose adjustments for pregnancy have been established. Pregnancy may alter pharmacokinetics (e.g., increased volume of distribution, altered clearance), but data are insufficient to recommend dose changes. Use with caution and monitor for toxicity.
Monitor for diarrhea, which can be severe; consider loperamide and hydration. Assess for interstitial lung disease (ILD) and hepatotoxicity. Dose reduction required for severe renal impairment (Cr Cl 15–29 m L/min). For patients with EGFR exon 19 deletion or exon 21 L858R mutation, first-line use improves PFS. Avoid P-glycoprotein strong inducers (e.g., rifampin) during treatment.
Premedicate with corticosteroids (e.g., dexamethasone 20 mg IV) 1 hour before infusion to reduce the risk of cytokine release syndrome (CRS). Monitor for neurological toxicities, including seizures and encephalopathy, especially during the first 2 doses. Dose adjustments are required for patients with renal impairment (Cr Cl < 30 m L/min). Blinatumomab is administered as a continuous IV infusion over 28 days per cycle; do not flush the line to prevent bolus administration.
Take afatinib at least 1 hour before or 2 hours after a meal.,Do not crush, chew, or split tablets; swallow whole with water.,Seek medical help for severe or persistent diarrhea, cough, or difficulty breathing.,Avoid grapefruit and Seville oranges during treatment.,Report signs of liver problems (yellowing skin/eyes, dark urine).,Use effective contraception during and for 2 weeks after stopping therapy.,Avoid direct sunlight exposure; use sunscreen.
This medication is given as a continuous infusion through a vein over 28 days; you will have a portable infusion pump.,Common side effects include fever, chills, headache, and nausea; these are often manageable with medications.,Seek immediate medical attention if you experience severe headache, confusion, seizures, difficulty speaking, or vision changes (signs of neurological toxicity).,Report any signs of infection such as fever, chills, or sore throat; blinatumomab can lower your white blood cell count.,Do not disconnect, adjust, or stop the infusion pump without consulting your healthcare provider.
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
"The combination of afatinib, a tyrosine kinase inhibitor, with pantoprazole, a proton pump inhibitor (PPI), can lead to reduced absorption of afatinib due to elevated gastric pH. Afatinib exhibits pH-dependent solubility, and higher gastric pH decreases its dissolution and bioavailability, potentially reducing its therapeutic efficacy. This interaction may result in suboptimal plasma concentrations of afatinib, increasing the risk of treatment failure in patients with non-small cell lung cancer."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFATINIB vs BLINCYTO, answered by our medical review team.
AFATINIB is a Tyrosine Kinase Inhibitor Antineoplastic that works by Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.. BLINCYTO is a Antineoplastic Monoclonal Antibody that works by Bispecific CD19-directed CD3 T-cell engager; binds CD19 on B cells and CD3 on T cells, activating endogenous T cells to lyse CD19-expressing B cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFATINIB and BLINCYTO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFATINIB is: 40 mg orally once daily, continuously.. The standard adult dose of BLINCYTO is: Continuous intravenous infusion over 28 days per cycle. For patients ≥45 kg: 9 mcg/day on days 1-7 and 28 mcg/day on days 8-28 for cycle 1, then 28 mcg/day on days 1-28 for subsequent cycles. For patients <45 kg: 5 mcg/m2/day on days 1-7 and 15 mcg/m2/day on days 8-28 for cycle 1, then 15 mcg/m2/day on days 1-28 for subsequent cycles. Hospitalization recommended for first 9 days of cycle 1 and first 2 days of subsequent cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFATINIB and BLINCYTO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFATINIB is classified as Category C. Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neura. BLINCYTO is classified as Category C. Based on its mechanism of action (CD19-directed bispecific T-cell engager) and animal studies, blinatumomab may cause fetal harm. IgG molecules cross the placenta, with increasing . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.